
Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Catch up on what to expect at this year's RAD conference in Nashville, Tennessee.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The OS-01 peptide formulation enhanced skin barrier function and reduced inflammation, showing promising results in a 12-week clinical trial.

Tristan Hasbargen, PA-C, led a hands-on suturing workshop at the Fall Clinical NP/PA Conference, enhancing skills in surgical dermatology.

Zasocitinib emerges as a promising oral therapy for psoriasis and psoriatic arthritis, showcasing superior selectivity and safety compared to traditional JAK inhibitors.

Acne is increasingly recognized as a chronic condition, affecting diverse populations and demanding innovative treatment strategies and equitable care access.

In part 3 of this conversation, Adam Friedman, MD, FAAD, discusses the need for unity in advancing lichen planus care and research.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Market pullbacks tempt investors to time the market, but history shows staying invested beats guessing the highs and lows—time > timing.

Jonathan Silverberg, MD, PhD, MPH, walks through what to look out for in AD management.

Discover the latest advancements in dermatology in our June issue, including FDA approvals, innovative treatments, and expert insights shaping patient care today.

In part 2 of this conversation, Adam Friedman, MD, FAAD, discusses new data on lichen planus treatment trends, unmet needs, and the promise of innovative therapies.

Sagimet Biosciences reveals denifanstat's promising phase 3 results, offering a novel oral treatment for moderate to severe acne with significant efficacy.

This review of the latest dermatologic studies includes insights into clinical manifestations of mpox infection, therapeutic modulation of Demodex density via isotretinoin, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

New research highlights the importance of tinted sunscreens with iron oxides for effective protection against visible light-induced skin pigmentation, especially for darker skin tones.

Jonathan Silverberg, MD, PhD, MPH, shares his insights on treating and managing CHE.

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

Explore cutting-edge insights and networking opportunities at this year's Fall Clinical Dermatology Conference for PAs and NPs, focusing on dermatology education and innovative treatments.

Friedman discusses survey findings revealing inconsistent screening, outdated assumptions, and lack of FDA-approved therapies for lichen planus.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Catch up on coverage from the last day of the 2025 Fall Clinical Dermatology Conference for PAs and NPs held in Orlando, Florida.

Clinicians learn to navigate salary negotiations and contracts effectively, focusing on value and strategic insights for career empowerment.

Heather Gates, PA-C, shares insights on the importance of continuous learning, mentorship, and legislative reform for PAs and NPs in dermatology.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Evan Rieder, MD, shares effective strategies to enhance dermatology practice efficiency by addressing psychological aspects of patient care and setting professional boundaries.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Recludix advances REX-8756, a first-in-class oral STAT6 inhibitor, showing promise for safer, targeted treatment of type 2 inflammatory skin diseases.